BRIEF published on 08/28/2024 at 13:05, 2 years 1 month ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 2 years 1 month ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 2 years 1 month ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
BRIEF published on 08/21/2024 at 13:05, 2 years 1 month ago La théralase démontre l'activation de la rutherrine avec un médicament contre le diabète Traitement Du Cancer Theralase Rutherrin Metformine Production De ROS
PRESS RELEASE published on 08/21/2024 at 13:00, 2 years 1 month ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
BRIEF published on 08/12/2024 at 13:05, 2 years 1 month ago Theralase publie ses états financiers du deuxième trimestre 2024 Résultats Financiers Placements Privés Traitement Du Cancer Theralase Étude II
BRIEF published on 08/12/2024 at 13:05, 2 years 1 month ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 2 years 1 month ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 2 years 2 months ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
BRIEF published on 07/08/2024 at 23:20, 2 years 2 months ago Theralase clôture une première tranche de placement privé de 775 000 $CAN Placement Privé Recherche Contre Le Cancer Theralase Rutherrin Étude Clinique De Phase II
Published on 10/01/2026 at 08:02, 1 hour 39 minutes ago Southern Energy Announces Results of Annual Meeting and Board Changes
Published on 10/01/2026 at 01:21, 8 hours 20 minutes ago Revival Gold Announces Filing of Final Base Shelf Prospectus
Published on 10/01/2026 at 01:00, 8 hours 41 minutes ago Algo Grande Copper Secures Five-Year Surface Access Agreement With Ejido Palos Chinos at the Adelita Project
Published on 09/30/2026 at 23:30, 10 hours 11 minutes ago Early Warning News Release Issued with Respect to the Acquisition of Securities of Cypher Metaverse Inc.
Published on 09/30/2026 at 20:35, 13 hours 6 minutes ago Fairplay Ventures Inc. Enters Into Definitive Agreement to Complete Qualifying Transaction With Ampere Metals Pty. Limited
Published on 10/01/2026 at 09:38, 3 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: 2026 Notice of Annual General Meeting – FY27 LTI Grant
Published on 10/01/2026 at 09:25, 16 minutes ago centrotherm reports solid first-half results for 2026 in a challenging market environment
Published on 10/01/2026 at 09:10, 31 minutes ago COSRX Becomes the First K-Beauty Brand to Sponsor Maison Margiela at Paris Fashion Week
Published on 10/01/2026 at 09:05, 36 minutes ago FORCYD expands into Switzerland and appoints Bob Dillen as Partner to lead Swiss practice
Published on 10/01/2026 at 09:05, 36 minutes ago H.I.G. Capital Announces the Sale of Pinalli to Borletti Group
Published on 10/01/2026 at 08:30, 1 hour 11 minutes ago Eurazeo opens an office in Abu Dhabi, reinforcing its commitment to the Middle East
Published on 10/01/2026 at 08:30, 1 hour 11 minutes ago Cegedim Business Services dévoile Hospi-DM, sa nouvelle offre SaaS de traçabilité des dispositifs médicaux, lors des 36èmes Journées Euro-Pharmat
Published on 10/01/2026 at 08:30, 1 hour 11 minutes ago Eurazeo ouvre un bureau à Abu Dhabi et renforce son engagement au Moyen-Orient
Published on 10/01/2026 at 08:00, 1 hour 41 minutes ago CNP Assurances and Embracon complete their combination to create a leading consórcio player in Brazil
Published on 10/01/2026 at 08:00, 1 hour 41 minutes ago CNP Assurances et Embracon finalisent leur rapprochement pour former un acteur majeur du consórcio au Brésil
